Xeljanz receives positive reimbursement decision in England

The UK’s HTA body NICE has provided final guidance recommending Xeljanz (tofacitinib citrate) as a treatment option for adults with severe active rheumatoid arthritis.

The decision means Pfizer’s JAK inhibitor will be reimbursed on the National Health Service in England.

The recommendation applies to adults whose disease has responded inadequately to intensive therapy with conventional or other disease-modifying anti-rheumatic drugs (DMARDs).

It can also be used as a monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.